Bicalutamide and spironolactone are being compared for their effectiveness and safety in treating female pattern hair loss. The conversation seeks advice on which is better to use.
The user wants to try using 0.025% topical finasteride every day by diluting their 0.1% topical finasteride with alfatradiol, and is asking if it's possible to mix them or if there are other options. They heard that alfatradiol might not be suitable for this purpose.
Finasteride and minoxidil are recommended as first-line treatments for hair loss, with dutasteride and oral minoxidil as stronger options if needed. Hair transplants should only be considered after achieving stability with medication, and non-surgical options are suggested if medications are ineffective.
Hair loss treatments Fin and Minoxidil failed for user. Suggested alternatives are 75mg oral spiro and RU58841, but concerns about low testosterone and self-esteem were raised.
Finasteride is the most effective treatment for reducing DHT and addressing hair loss compared to fish oil and saw palmetto. Topical treatments like RU58841 and minoxidil are also discussed, but finasteride remains the most effective option.
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
A 26-year-old individual treating hair loss since 19, using a regimen of Finasteride, Cyproterone, Oral Minoxidil, Microneedling, Dutasteride, and newly added RU58841. They're seeking advice from other RU58841 users about their experiences.
Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.
Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgenreceptors locally and may be available by late 2026 or early 2027.
Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgenreceptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.
The user reports temple hair regrowth using RU58841, minoxidil, and finasteride, recently switching to dutasteride. They consider stopping RU58841 and continuing with oral minoxidil and dutasteride.
Finasteride, dutasteride, saw palmetto, caffeine, spironolactone, acetyltetrapeptides, tea tree oil, hydrocortisone, zinc pyrithione, latanoprost, melatonin, marine protein supplements, PRP, microneedling, and valproate are discussed as treatments for hair loss. DHT reduction and inflammation control are key strategies.
A 17-year-old is concerned about potential hair loss due to maternal genetics and wonders if treatments like Minoxidil, Finasteride, or RU58841 will be effective. They hope their paternal genetics will help prevent hair loss or make treatments more effective.
A non-binary individual experienced hair loss after stopping hormone replacement therapy and is using oral Dutasteride, oral Minoxidil, and ketoconazole shampoo. They are hopeful for regrowth but may use wigs due to the high cost and uncertain effectiveness of additional treatments like mesotherapy and PRP.
The user experienced temple recession, shedding, and acne while on 0.5mg dutasteride, 1.25mg finasteride every other day, and 5mg oral minoxidil daily. They are considering switching treatments due to worsening symptoms and are contemplating using a topical anti-androgen like RU58841.
Zinc picolinate and saw palmetto may lower DHT but are less effective than finasteride. Finasteride and minoxidil are preferred treatments, with ketoconazole shampoo as a suggested addition.
The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
A user experienced androgenic alopecia starting at the vertex without frontal hairline recession and is seeking information on this pattern. Another user noted that vertex or diffuse hair loss is common among men.
Transitioning from finasteride to Pyrilutamide as a treatment for hair loss, and the potential risks associated with taking such a drug. People have discussed the need to wait at least 6 months in order to assess results, and are willing to risk their health trying this new medication.
A user with low-normal testosterone levels is considering starting finasteride and minoxidil for hair loss but is concerned about hormone imbalance. They are advised that finasteride targets DHT, not testosterone, and could start with minoxidil while making lifestyle changes to naturally increase testosterone.
The user received trichotest results indicating finasteride is ineffective for them, and they plan to use dutasteride mesotherapy and add cetirizine to minoxidil. They seek advice on incorporating dutasteride into their regimen.
A user's regimen to help with their diffuse thinning, which includes taking Pyrilutamide BID, 1mg finasteride daily, 2.5mg oral minoxidil daily, topical minoxidil since August 2021, LLLT every two days, topical fin, progesterone, melatonin, minoxidil (started one week ago), pumpkin seed oil and not dermarolling; other commenters suggested Nizoral for dandruff control and caution when using pre-mixed products with Pyrilutamide.
The conversation is about the possibility of obtaining Pyrilutamide, a hair loss treatment, once it becomes available in China, despite it not being approved by the US FDA yet. The user wants to use Pyrilutamide along with other treatments.
Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.
A 21-year-old male suffering from male pattern baldness is using topical finasteride and minoxidil, and oral minoxidil. His bloodwork shows normal DHT levels and slightly high testosterone, leading to discussions about the role of DHT sensitivity in hair loss, the potential impact of finasteride on his DHT levels, and the suggestion to proceed with oral finasteride due to his high testosterone.
Finasteride and oral minoxidil effectively maintain a youthful appearance and full head of hair, despite genetic predispositions to balding. The discussion also considers the impact of DHT blockers on masculinity and aging, with lifestyle choices like sunscreen use and a vegetarian diet mentioned.
The conversation is about the effects of steroids on hair loss. Some users believe that steroids can cause hair loss, while others argue that it depends on individual sensitivity to DHT. There is also discussion about the appearance of balding individuals who use steroids.
The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.